Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTCT Stock Forecast 2025-2026
$49.53
Current Price
$3.91B
Market Cap
Buy 9
Hold 4
Sell 2
Wall St Analyst Ratings
Distance to PTCT Price Targets
+128.1%
To High Target of $113.00
+28.2%
To Median Target of $63.50
-19.2%
To Low Target of $40.00
PTCT Price Momentum
+2.8%
1 Week Change
-8.7%
1 Month Change
+73.4%
1 Year Change
+9.7%
Year-to-Date Change
-15.2%
From 52W High of $58.38
+106.4%
From 52W Low of $24.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching PTC Therapeutics (PTCT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PTCT and similar high-potential opportunities.
Latest PTCT Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, PTCT has a bullish consensus with a median price target of $63.50 (ranging from $40.00 to $113.00). The overall analyst rating is Buy (7.6/10). Currently trading at $49.53, the median forecast implies a 28.2% upside. This outlook is supported by 9 Buy, 4 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 128.1% upside. Conversely, the most conservative target is provided by Joseph Thome at TD Cowen, suggesting a 19.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTCT Analyst Ratings
9
Buy
4
Hold
2
Sell
PTCT Price Target Range
Low
$40.00
Average
$63.50
High
$113.00
Current: $49.53
Latest PTCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 22, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $65.00 |
| Mar 31, 2025 | JP Morgan | Eric Joseph | Overweight | Maintains | $75.00 |
| Mar 14, 2025 | JP Morgan | Eric Joseph | Overweight | Maintains | $78.00 |
| Mar 11, 2025 | B of A Securities | Tazeen Ahmad | Neutral | Upgrade | $55.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $70.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Perform | Initiates | $55.00 |
| Feb 28, 2025 | JP Morgan | Eric Joseph | Overweight | Maintains | $72.00 |
| Feb 18, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $63.00 |
| Feb 12, 2025 | Citigroup | David Lebowitz | Sell | Maintains | $45.00 |
| Feb 3, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $113.00 |
| Jan 15, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $76.00 |
| Dec 13, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Upgrade | $67.00 |
| Dec 4, 2024 | Goldman Sachs | Paul Choi | Sell | Maintains | $42.00 |
| Dec 4, 2024 | Citigroup | David Lebowitz | Sell | Maintains | $32.00 |
| Dec 3, 2024 | Barclays | Gena Wang | Equal-Weight | Maintains | $56.00 |
| Dec 3, 2024 | UBS | Colin Bristow | Buy | Maintains | $71.00 |
| Dec 3, 2024 | Baird | Joel Beatty | Outperform | Maintains | $70.00 |
| Nov 27, 2024 | Baird | Joel Beatty | Outperform | Maintains | $52.00 |
| Nov 26, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $68.00 |
| Nov 19, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $62.00 |
Ptc Therapeutics Inc. (PTCT) Competitors
The following stocks are similar to PTC Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PTCT
PTC Therapeutics
mkt cap
3.91B
Ptc Therapeutics Inc. (PTCT) Financial Data
Ptc Therapeutics Inc. has a market capitalization of $3.91B with a P/E ratio of -10.5x. The company generates $806.78M in trailing twelve-month revenue with a -45.0% profit margin.
Revenue growth is -30.6% quarter-over-quarter, while maintaining an operating margin of -7.4% and return on equity of +33.1%.
Valuation Metrics
Market Cap
$3.91B
Enterprise Value
$5.22B
P/E Ratio
-10.5x
PEG Ratio
-13.5x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
-30.6%
Gross Margin
+92.4%
Operating Margin
-7.4%
Net Margin
-45.0%
EPS Growth
-30.6%
Financial Health
Cash/Price Ratio
+29.5%
Current Ratio
2.4x
Debt/Equity
-2.3x
ROE
+33.1%
ROA
-5.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ptc Therapeutics Inc. (PTCT) Business Model
About Ptc Therapeutics Inc.
What They Do
Develops medicines for rare genetic disorders.
Business Model
The company focuses on discovering and commercializing innovative treatments for rare genetic disorders, primarily using its proprietary technologies like Translarna. Ptc Therapeutics generates revenue through the development and sale of therapies that target specific genetic mutations, addressing significant unmet medical needs in both rare diseases and oncology.
Additional Information
Ptc Therapeutics is headquartered in the United States and operates globally, collaborating with research institutes and industry partners to enhance drug development. The company is committed to advancing scientific research and improving the quality of life for patients with rare genetic conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
939
CEO
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Country
United States
IPO Year
2013
Website
www.ptcbio.comPtc Therapeutics Inc. (PTCT) Latest News & Analysis
Latest News
Quick Summary
PTC Therapeutics received a positive opinion from the EMA for Sephience™ (sepiapterin) to treat PKU, with European launch preparations underway.
Why It Matters
Positive EMA opinion for Sephience™ enhances PTC Therapeutics' market potential in Europe, potentially boosting revenue and investor confidence in the company's growth trajectory.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present at the Bank of America Securities 2025 Health Care Conference on May 13 at 10:00 a.m.
Why It Matters
PTC Therapeutics' executives speaking at a major conference could indicate upcoming developments or insights, potentially impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
11 days ago
Quick Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast on May 6 at 4:30 p.m. to report Q1 2025 financial results and discuss business updates.
Why It Matters
PTC Therapeutics' upcoming webcast on financial results and business outlook will provide insights into its performance and future prospects, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PTC Therapeutics (PTCT) is not expected to meet key criteria for a potential earnings beat in its upcoming report, according to recent analysis.
Why It Matters
PTC Therapeutics may report disappointing earnings, indicating potential stock underperformance and signaling caution for investors regarding future profitability.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Vaccine stocks fall following FDA resignation
27 days ago
Quick Summary
Dr. Kavita Patel discussed the effects of FDA and HHS changes on vaccines and public health policy on 'Fast Money,' highlighting potential implications for the healthcare sector.
Why It Matters
Changes in FDA and HHS policies can influence vaccine development and public health initiatives, affecting healthcare stocks and overall market sentiment in the health sector.
Source: CNBC Television
Market Sentiment:
Negative
Quick Summary
PTC Therapeutics announced that the European Commission will withdraw its drug for inherited progressive muscle-wasting disorder following a negative advisory panel opinion.
Why It Matters
PTC Therapeutics losing EU approval for its muscle-wasting disorder drug can impact its revenue and stock price, signaling potential challenges in regulatory pathways and market trust.
Source: Reuters
Market Sentiment:
Negative
Frequently Asked Questions About PTCT Stock
What is Ptc Therapeutics Inc.'s (PTCT) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Ptc Therapeutics Inc. (PTCT) has a median price target of $63.50. The highest price target is $113.00 and the lowest is $40.00.
Is PTCT stock a good investment in 2025?
According to current analyst ratings, PTCT has 9 Buy ratings, 4 Hold ratings, and 2 Sell ratings. The stock is currently trading at $49.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTCT stock?
Wall Street analysts predict PTCT stock could reach $63.50 in the next 12 months. This represents a 28.2% increase from the current price of $49.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ptc Therapeutics Inc.'s business model?
The company focuses on discovering and commercializing innovative treatments for rare genetic disorders, primarily using its proprietary technologies like Translarna. Ptc Therapeutics generates revenue through the development and sale of therapies that target specific genetic mutations, addressing significant unmet medical needs in both rare diseases and oncology.
What is the highest forecasted price for PTCT Ptc Therapeutics Inc.?
The highest price target for PTCT is $113.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 128.1% increase from the current price of $49.53.
What is the lowest forecasted price for PTCT Ptc Therapeutics Inc.?
The lowest price target for PTCT is $40.00 from Joseph Thome at TD Cowen, which represents a -19.2% decrease from the current price of $49.53.
What is the overall PTCT consensus from analysts for Ptc Therapeutics Inc.?
The overall analyst consensus for PTCT is bullish. Out of 26 Wall Street analysts, 9 rate it as Buy, 4 as Hold, and 2 as Sell, with a median price target of $63.50.
How accurate are PTCT stock price projections?
Stock price projections, including those for Ptc Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 4:55 AM UTC